PACLITAXEL ENCAPSULATED IN PLGA NANOPARTICLES FOR LUNG CANCER THERAPY

Lung cancer is a type of cancer that has a high occurrence and fatality rate in Brazil and globally. It is usually detected in advanced stages, which makes its prognosis difficult. In this context, researchers have explored novel proposals using nanotechnology to enhance the effectiveness and bioavailability of drugs for treating this type of cancer. In this study we have developed a nanostructured system from poly(lactic acid-co-glycolic acid) (PLGA) to release paclitaxel (PTX) in the treatment of lung cancer to modulate or enhance the action of this drug. We used a simple emulsion technique to develop polymeric nanoparticles (NPs) containing PTX. The NPs had an average diameter of 162±7 nm, polydispersity index (PDI) of 0.17±0,02 in, and zeta potential of -23±3 mV, also showing good stability for 3 months and encapsulation efficiency of 37±5 %. Microscopic analyses are underway to improve the characterization of the NPs as well as cellular viability assays. The development of these nanosystems is significant in the pursuit of suitable therapeutic approaches for managing lung cancer.